Gabapentinoids Not Directly Associated With Risk of Self-Harm

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on May 15, 2025.

By Elana Gotkine HealthDay Reporter

THURSDAY, May 15, 2025 -- Gabapentinoids are not associated with risk of self-harm in adults; however, elevated risk is seen before initiation of treatment, during the initial phase of treatment, and after discontinuation of treatment, according to a study published online April 30 in The BMJ.

Andrew S.C. Yuen, from University College London, and colleagues conducted a population-based self-controlled case series study to estimate the effect of gabapentinoid treatment on self-harm. Data were included for 10,002 adults with gabapentinoid prescriptions who had an incident event of self-harm between Jan. 1, 2000, and Dec. 31, 2020. Patient time was divided into four discrete windows: 90 days before treatment; the treatment period; 14 days after the treatment period; and the reference period (the person time that falls outside of the three other categories).

The researchers found that per 100 person-years, the incidence rate of self-harm was 16.79 in the 90 days before treatment, 9.66 in the treatment period, 29.60 in the 14 days after the treatment period, and 6.75 in the reference period. During the 90-day period before treatment, the risk of self-harm was increased, with an adjusted incidence rate ratio of 1.69. The risk of self-harm decreased gradually around the time of treatment initiation and returned to reference level during the treatment period. Within 14 days after treatment cessation, the adjusted incidence rate ratio for self-harm increased to 3.02. Throughout a series of subgroups and sensitivity analyses, the findings remained consistent.

"We observed that the association of gabapentinoids and risk of self-harm is multifaceted, and the association does not support a direct effect of gabapentinoid treatment on self-harm," the authors write.

One author disclosed ties to the pharmaceutical industry.

Abstract/Full Text

Editorial

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-05-16 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords